Journal ArticleDOI
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Joseph P. McEvoy,Jeffrey A. Lieberman,T. Scott Stroup,Sonia M. Davis,Herbert Y. Meltzer,Robert A. Rosenheck,Marvin S. Swartz,Diana O. Perkins,Richard S.E. Keefe,Clarence E. Davis,Joanne B. Severe,John K. Hsiao +11 more
TLDR
For patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypicals antipsychotics.Abstract:
Objective: When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation. Method: Ninety-nine patients who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily because of inadequate efficacy, were randomly assigned to open-label treatment with clozapine (N=49) or blinded treatment with another newer atypical antipsychotic not previously received in the trial (olanzapine [N=19], quetiapine [N= 15], or risperidone [N=16]).read more
Citations
More filters
Journal ArticleDOI
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Stefan Leucht,Caroline Corves,Caroline Corves,Dieter Arbter,Rolf R. Engel,Chunbo Li,Chunbo Li,John M. Davis +7 more
TL;DR: A meta-analysis of randomised controlled trials to compare the effects of second-generation antipsychotic drugs in patients with schizophrenia provided data for individualised treatment based on efficacy, side-effects, and cost.
Journal ArticleDOI
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Jari Tiihonen,Jari Tiihonen,Jouko Lönnqvist,Kristian Wahlbeck,Timo Klaukka,Leo Niskanen,Antti Tanskanen,Jari Haukka +7 more
TL;DR: Although the proportional use of second-generation antipsychotic drugs rose from 13% to 64% during follow-up, the gap in life expectancy between patients with schizophrenia and the general population did not widen between 1996 and 2006.
Journal ArticleDOI
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe,Robert M. Bilder,Sonia M. Davis,Philip D. Harvey,Barton W. Palmer,James M. Gold,Herbert Y. Meltzer,Michael F. Green,George Capuano,T. Scott Stroup,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Clarence E. Davis,John K. Hsiao,Jeffrey A. Lieberman +16 more
TL;DR: After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.
Journal ArticleDOI
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Robert W. Buchanan,Julie Kreyenbuhl,Julie Kreyenbuhl,Deanna L. Kelly,Jason M. Noel,Douglas L. Boggs,Bernard A. Fischer,Seth Himelhoch,Beverly Fang,Eunice Peterson,Patrick R. Aquino,William R. Keller +11 more
TL;DR: An extensive literature review was conducted to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest.
Journal ArticleDOI
Neurobiology of schizophrenia.
Christopher A. Ross,Russell L. Margolis,Sarah A. J. Reading,Mikhail V. Pletnikov,Joseph T. Coyle +4 more
TL;DR: In this paper, the authors identify proteins of candidate genetic risk factors for schizophrenia, including dysbindin, neuregulin 1, DAOA, COMT, and DISC1.
References
More filters
Journal ArticleDOI
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
TL;DR: Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
TL;DR: In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.
Journal ArticleDOI
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development
T. Scott Stroup,Joseph P. McEvoy,Marvin S. Swartz,Matthew J. Byerly,Ira D. Glick,José M. Cañive,Mark McGee,George M. Simpson,Michael C. Stevens,Jeffrey A. Lieberman +9 more
TL;DR: The CATIE schizophrenia trial blends features of efficacy studies and large, simple trials to create a pragmatic trial that will provide extensive information about antipsychotic drug effectiveness over at least 18 months.
Journal ArticleDOI
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials
TL;DR: It is confirmed that treatment-resistant schizophrenic patients have more favorable outcomes when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total score, categorical response rate, Scale for the Assessment of Negative Symptoms score, Simpson-Angus Rating Scale score, and compliance rate.
Related Papers (5)
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Herbert Y. Meltzer,Larry Alphs,Alan I. Green,A. Carlo Altamura,Ravi Anand,Alberto Bertoldi,Marc Bourgeois,Guy Chouinard,M. Zahur Islam,John M. Kane,Ranga Krishnan,Jean-Pierre Lindenmayer,Steven G. Potkin,Saide Altinsan,Siemion Altman,Likiana Avigo,Richard Balon,Vanda Benešová,Luis Bengochea,István Bitter,Elisabeth Bokowska,Bernardo Carpiniello,Daniel E. Casey,Giovanni B. Cassano,James C.-Y. Chou,Libor Chvila,Jean Dalery,Pedro L. Delgado,Liliana Dell'Osso,Carl Eisdorfer,Robin Emsley,Dawn Eng,Tom A. Fahy,Vera Folnegovic,Sophie Frangou,Pedro Gargoloff,Alberto Giannelli,Ira D. Glick,Richard Greenberg,George T. Grossberg,Doris Gundersen,Hannale Heila,George Hsu,Naveed Iqbal,Miro Jakovljević,Richard C. Josiassen,Akos Kassaifarkas,Robert Kerwin,Frederic Khidichian,Mary Ann Knesevich,Jack S. Krasuski,Vinod Kumar,Veronica W. Larach,Michael D. Lesem,Shôn Lewis,Pierre-Michel Llorca,H. Edward Logue,Stephen Martin,Muriel Maurel-Raymondet,Laszlo Mod,Eva Morik,Carlos Morra,Ann M. Mortimer,Mojtaba Noursalehi,Gyorgy Ostorharics-Horvath,Ivo Paclt,Jörg Pahl,Linda Pestreich,J. L. Peters,Rosario Pioli,Michael G. Plopper,Thomas Posever,Mark Hyman Rapaport,Delbert Robinson,Carlo Andrea Robotti,Harry Rohme,Frédéric Rouillon,David A. Sack,Isaac Sakinsofsky,Phillip Seibel,George M. Simpson,Nancy Temkin,Oladapo Tomori,Santha Vaidain,Zdeòka Vyhnándová,Frederick Young,Daniel L. Zimbroff,Marie Agathe Zimmerman +87 more